A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 680 participants.
Also called NCT05953480
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 680 participants
- Sponsor
- Registry
-
NCT05953480 -
2022-501890-38-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Belgium, China, Czechia, Finland, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Japan, Serbia, Singapore, South Korea, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05953480. Randomized; double masking; primary purpose treatment. Start 2023-07-14 (actual); primary completion 2026-06-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
- Acronym
- Revive
- Condition
- Acute Ischemic Stroke
- Intervention (Biological)
- Redasemtide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shionogi
Record details
- Record id
cardio:ct-nct05953480- Content hash
1c7be906d778b60cecd4d2224da0bc05b4f9b00911ab174a78f67594d9a21b80